Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Give CNAs a career ladder to climb.

Provider (Washington, D.C.)·2001
Same author

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.

British journal of cancer·2001
Same author

Exploring hemichannel permeability in vitro.

Methods in molecular biology (Clifton, N.J.)·2001
Same author

Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.

Oncogene·2001
Same author

A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Cancer research·2001

Related Experiment Video

Updated: Jun 22, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Targeting gene expression to hypoxic tumor cells

G U Dachs1, A V Patterson, J D Firth

  • 1Experimental Oncology Division, Medical Research Council, Harwell, UK.

Nature Medicine
|May 1, 1997
PubMed
Summary

Solid tumors with low oxygen (hypoxia) resist treatment. This study shows how hypoxia can activate gene expression for targeted cancer therapy using the hypoxia-inducible factor-1 (HIF-1) and hypoxia-responsive element (HRE) system.

More Related Videos

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
09:17

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Published on: August 2, 2018

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Related Experiment Videos

Last Updated: Jun 22, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
09:17

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Published on: August 2, 2018

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Solid tumors often contain hypoxic regions.
  • Hypoxia in tumors is associated with poor prognosis and resistance to therapy.
  • Tumor hypoxia poses a significant challenge in cancer treatment.

Purpose of the Study:

  • To investigate the potential of exploiting tumor hypoxia for targeted gene expression.
  • To demonstrate the activation of heterologous gene expression in hypoxic tumor cells.
  • To explore the utility of the hypoxia-inducible factor-1 (HIF-1)/hypoxia-responsive element (HRE) system in cancer therapy.

Main Methods:

  • Utilized the hypoxia-responsive element (HRE) to drive gene expression.
  • Investigated the interaction between HRE and the hypoxia-inducible factor-1 (HIF-1) transcriptional complex.
  • Assessed gene regulation in hypoxic tumor cell environments.

Main Results:

  • Demonstrated that the HIF-1/HRE system is active in hypoxic tumor cells.
  • Confirmed the ability to activate heterologous gene expression under hypoxic conditions.
  • Showcased the potential for targeted gene delivery in tumors.

Conclusions:

  • The HIF-1/HRE system can be effectively utilized to target gene expression within hypoxic tumors.
  • Exploiting tumor-specific hypoxic conditions offers a promising strategy for cancer therapy.
  • This approach holds potential for the targeted delivery of diagnostic or therapeutic genes.